阿洛伊-埃莫丁通过调节HIF-1α来调节结肠上皮细胞功能,以减轻刺激性肠综合征
Qinghua Wang1, Shiyu Lu2, Zhonghao Yin3
1Department of Spleen and Gastroenterology, Nanjing Jiangning Hospital of Traditional Chinese Medicine, Nanjing, China.
Xenobiotica; the fate of foreign compounds in biological systems
|September 11, 2025
概括
-埃莫丁 (AE) 通过减少炎症和改善肠道屏障功能,有效治疗易怒肠综合征 (IBS). 它通过调节结肠中缺氧诱导因子-1α (HIF-1α) 的表达而起作用.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 刺激性肠综合征 (IBS) 是一种普遍存在的胃肠疾病,其特点是腹痛,胀气和改变肠道习惯.
- 目前的IBS治疗效果有限,并可能产生显著的副作用,需要探索新的治疗药物.
- -埃莫丁 (AE) 是一种具有潜在抗炎和细胞保护性能的天然化合物.
研究的目的:
- 在刺激性肠综合征 (IBS) 的老鼠模型中研究-埃莫丁 (AE) 的治疗潜力.
- 阐明AE对IBS症状产生影响的潜在分子机制.
- 评估低氧诱导因子-1α (HIF-1α) 在AE治疗作用中的作用.
主要方法:
- 使用脱氧醇酸 (DCA) 诱导了一种IBS大鼠模型.
- AE是口服的,IBS症状通过体重,便产量,焦虑类行为 (开放场测试),内脏过敏性 (AWR得分) 和结肠透性 (FITC-dextran测试) 来评估.
- 使用ELISA量化了P (SP),5-hydroxytryptamine (5-HT),TNF-α和IL-6的水平,并通过qRT-PCR分析了HIF-1α的表达. 在体外研究中使用了用LPS处理的NCM460细胞.
主要成果:
- 治疗AE显著缓解IBS症状,包括改善体重增加,减少便中的水含量,减少焦虑,减轻内脏过敏.
- 服用AE降低了结肠的通透性,降低了SP,5-HT和促炎细胞因子 (TNF-α,IL-6) 的水平.
- 在IBS大鼠的结肠组织和LPS治疗的NCM460细胞中,AE抑制了HIF-1α的上调. HIF-1α过度表达逆转了AE的保护作用,表明其关键作用.
结论:
- -埃莫丁 (AE) 显示出对刺激性肠综合征 (IBS) 的显著治疗潜力.
- AE通过增强结肠上皮细胞增殖,减少透性和减轻炎症来改善IBS症状.
- AE的治疗效果至少部分通过调节低氧诱导因子-1α (HIF-1α) 信号传输来调节.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
636
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
636
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Drugs for Treatment of Constipation-Predominant IBS
732
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
732
Irritable Bowel Syndrome I: Introduction
929
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
929
Inflammatory Bowel Disease I: Ulcerative Colitis
904
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
904
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
644
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644


